A multi-center pivotal study assessing TT-11 CD30 CAR T-cell therapy
Latest Information Update: 21 Jan 2021
At a glance
- Drugs TT 11 (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors Tessa Therapeutics
- 21 Jan 2021 New trial record
- 18 Jan 2021 According to a Tessa therapeutics media release, this trial will be recruiting patients from more than 20 cancer centers across the US and Europe including sites in Italy, Spain and Sweden. The trial is expected to commence in USA in 2021.